<DOC>
	<DOC>NCT01860586</DOC>
	<brief_summary>The purpose of this study is to examine the effects of a drug called bevacizumab (Avastin) on the rates of recurrent retinal detachment and scar tissue formation.</brief_summary>
	<brief_title>Eye Injections of Bevacizumab to See if Medication Helps to Lower Risk of Scar Tissue Development in the Retina and Repeated Retinal Detachment.</brief_title>
	<detailed_description />
	<mesh_term>Retinal Detachment</mesh_term>
	<mesh_term>Dissociative Disorders</mesh_term>
	<mesh_term>Vitreoretinopathy, Proliferative</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Ability to provide written informed consent and comply with study assessments for the full duration of the study Undergoing pars plana vitrectomy with or without scleral buckling for recurrent RD due to PVR with planned silicone oil instillation. Prior antiVEGF (vascular endothelial growth factor) injections within 3 months of retinal detachment surgery. Traction retinal detachment due to proliferative diabetic retinopathy. Inability to flatten retina completely intraoperatively Known allergy or contraindication to intravitreal bevacizumab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>pvr</keyword>
	<keyword>rd</keyword>
	<keyword>Proliferative Vitreoretinopathy</keyword>
	<keyword>retinal detachment</keyword>
	<keyword>detachment</keyword>
</DOC>